Skip to search formSkip to main contentSkip to account menu

avagacestat

Known as: (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)- 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

BMS 708163

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Nonclinical Safety Assessment of the &ggr;-Secretase Inhibitor Avagacestat
The toxicity of avagacestat, a sulfonamide-based gamma (γ)-secretase inhibitor that was in development as a treatment for… 
Highly Cited
2015
Highly Cited
2015
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
IMPORTANCE Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to… 
Highly Cited
2015
Highly Cited
2015
The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis
Hepatic stellate cells (HSCs) known as “master producers” and macrophages as “master regulators”, are the key cell types that… 
Review
2014
Review
2014
Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches
The prevailing theory regarding Alzheimer disease (AD) is that insoluble amyloid β‐peptide (Aβ) plays a critical role in the… 
Highly Cited
2013
Highly Cited
2013
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
A hallmark of Alzheimer’s disease (AD) pathology is the accumulation of brain amyloid β-peptide (Aβ), generated by γ-secretase… 
2013
2013
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
AIM To evaluate the single dose pharmacokinetics, pharmacodynamics, and preliminary tolerability of the γ-secretase inhibitor BMS… 
Highly Cited
2012
Highly Cited
2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor… 
2012
2012
A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
Background and ObjectivesAvagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis… 
Highly Cited
2012
Highly Cited
2012
BMS-708,163 targets presenilin and lacks notch-sparing activity.
The "Notch-sparing" γ-secretase inhibitor (GSI) BMS-708,163 (Avagacestat) is currently in phase II clinical trials for Alzheimer… 
2012
2012
Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
BackgroundThe concentration of amyloid β (Aβ) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer’s disease (AD… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)